An independent group at the University of Minnesota will systematically review the evidence behind meningococcal and pneumococcal vaccination in children and young adults.
The Vaccine Integrity Project, based at the university's Center for Infectious Disease Research and Policy, announced the reviews this week. Executive Director Michael Osterholm said parents and clinicians need to trust that vaccine recommendations rest on a comprehensive and transparent review of the best available science, and that the need is especially important now, when "the federal vaccine review and recommendation process is not functioning as it historically has."
For families, the context matters more than the announcement. These two vaccines sit at the center of an unresolved dispute over the federal childhood schedule, and a parent looking up meningococcal vaccination this month can find two different answers depending on which document they read.
Inside the Two Reviews and the Evidence They Will Cover
The meningococcal review will assess every such vaccine licensed in the United States: those covering serogroups A, C, W and Y, known as MenACWY; serogroup B vaccines, or MenB; and newer pentavalent MenABCWY products. The second review will evaluate pneumococcal vaccines in children.
The work follows a series of independent evidence reviews the project has already produced, covering influenza, COVID-19 and RSV immunization, the hepatitis B birth dose, HPV vaccination, and Tdap vaccination during pregnancy.
Two disclosures belong with this. The project is funded by an unrestricted gift from Alumbra, a foundation established by philanthropist Christy Walton. And it is not a government body, so its reviews change no recommendation on their own.
The Federal Reclassification Is Currently on Hold
In January, the Department of Health and Human Services published a revised childhood immunization schedule that reduced the number of vaccines routinely recommended for all children. As CIDRAP reported at the time, MenACWY and MenB moved into a high-risk grouping, with meningococcal vaccination also appearing among the vaccines listed for shared clinical decision-making. Pneumococcal vaccination remained recommended for all children.
Those changes are not currently operative. A federal district court in Massachusetts issued a preliminary injunction in March in American Academy of Pediatrics v. Kennedy that stayed the January memo moving vaccines off the routine schedule, along with the reconstituted advisory committee's 2025 votes and the appointments of the members who cast them.
Guidance has therefore reverted to what was in place beforehand. The ruling was preliminary, and the litigation continues, so this can change. Parents who want to know what their own child's clinician is following should ask, since the American Academy of Pediatrics never adopted the narrower approach.
Serogroup Y Is Driving an Increase in a Rare but Dangerous Disease
Meningococcal disease, a bacterial infection caused by Neisseria meningitidis, is rare in the United States, but infections have increased since 2021, driven largely by serogroup Y, which is vaccine-preventable.
The disease is dangerous out of proportion to its frequency. CDC data indicate that 10 to 15 percent of meningococcal infections are fatal and that 10 to 20 percent of survivors have permanent aftereffects, including brain injury, limb amputation, or hearing loss. Invasive infection can progress within hours.
Pneumococcal disease, caused by Streptococcus pneumoniae, produces pneumonia, bloodstream infections and meningitis, with the greatest risk in young children and people with certain underlying conditions.
The uptake gap between the two meningococcal categories is already documented. In the 2025 National Immunization Survey-Teen, 90.8 percent of 17-year-olds had received the routinely recommended MenACWY vaccine. For MenB, which has been permissive since 2015 and under shared clinical decision-making since 2019, the figure was 36.3 percent. The vaccines cover different strains, so this is not a controlled comparison, but it shows what happens without a default.
Coverage and Access Questions Worth Raising Now
Insurance is the live household concern, because category assignment drives the federal requirement that private plans cover recommended vaccines without cost sharing. Under shared clinical decision-making, there is no default, and the decision is made one patient at a time between a clinician and a patient or parent. The category still carries coverage obligations, though surveys have found that many clinicians and patients do not know that.
Nothing here supports delaying a dose. No findings exist yet, and the reviews are designed to assess the evidence behind current recommendations rather than to propose new ones. A child due for an adolescent vaccine should be discussed at the next visit.
Three questions are reasonable to ask: whether a dose is covered by the family's plan this year and next, whether a child qualifies for the Vaccines for Children program, and, for MenB, whether a clinician recommends it, since a category with no default means that conversation may not start on its own.
What happens next: the project's reviews are underway, and American Academy of Pediatrics v. Kennedy will determine which federal schedule governs. MedicalDaily will report confirmed developments in both.
Key Questions Answered
Who is conducting the review? The Vaccine Integrity Project, based at the University of Minnesota's Center for Infectious Disease Research and Policy, an independent group with no regulatory authority.
Which vaccines are being reviewed? All licensed U.S. meningococcal vaccines, including MenACWY, MenB, and pentavalent MenABCWY products, plus pneumococcal vaccines, in children and young adults.
Is MenACWY still routinely recommended? Under current guidance, yes. The January reclassification is stayed by a court order and has no present effect.
How common is meningococcal disease? It is rare in the United States, but cases have risen since 2021, driven largely by serogroup Y.
How serious is it? CDC data indicate 10 to 15 percent of infections are fatal and 10 to 20 percent of survivors have permanent effects such as brain injury, limb amputation or hearing loss.
What does shared clinical decision-making mean? There is no default recommendation. The decision is made individually with a clinician, and the category still carries insurance coverage obligations.
Should families wait for the review before vaccinating? No. The reviews have produced no findings, and current recommendations stand. Discuss timing with a clinician rather than delaying.
